Literature DB >> 8367523

Measuring astatine-211 distributions with SPECT.

T G Turkington1, M R Zalutsky, R J Jaszczak, P K Garg, G Vaidyanathan, R E Coleman.   

Abstract

We have investigated standard SPECT techniques (rotating gamma cameras, multi-hole collimators, and filtered backprojection reconstruction) for imaging astatine-211 distributions. Since 211At emits alpha particles, this nuclide has potential for use in radiotherapy. The capability of imaging this nuclide would allow in vivo evaluation of the distribution and stability of potential 211At-labelled radiotherapeutic agents. 211At decay yields x-rays in the 77-92 keV range in addition to 500-900 keV gamma rays. This study evaluates the feasibility of SPECT imaging using the x-ray emissions of 211At. We have evaluated several collimators, with the determination that the medium-energy collimators we used are suitable, with 7% penetration (uncollimated counts versus collimated counts). Several phantoms were imaged and attenuation coefficients were measured (narrow-beam mu = 0.182 cm-1 for 77-80 keV x-rays in water). Reconstructed images demonstrate qualitative capabilities and a simple quantitative study demonstrates good correction for attenuation and scatter (approximately 10% error), at low count densities, at least for the phantom geometries used in this study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8367523     DOI: 10.1088/0031-9155/38/8/010

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  8 in total

1.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

2.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

3.  Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide.

Authors:  Kazunobu Ohnuki; Mitsuyoshi Yoshimoto; Hiromitsu Haba; Shino Manabe; Hiroki Takashima; Masahiro Yasunaga; Yasumasa Takenaka; Hirofumi Fujii
Journal:  EJNMMI Phys       Date:  2022-06-06

Review 4.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

Review 5.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

6.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774

7.  Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics.

Authors:  Cristina Müller; Christiaan Vermeulen; Ulli Köster; Karl Johnston; Andreas Türler; Roger Schibli; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2016-03-28

Review 8.  Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Authors:  Sture Lindegren; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Emma Aneheim
Journal:  Cancer Biother Radiopharm       Date:  2020-02-20       Impact factor: 3.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.